Cipla Breached Patent Rights by Slashing Cancer Drug Price: Bayer Pharma

German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week.
The Economic Times